Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$17.00 USD
-0.36 (-2.07%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $16.97 -0.03 (-0.18%) 7:32 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Cartesian Therapeutics, Inc. (RNAC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.60 | $45.00 | $39.00 | 139.63% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Cartesian Therapeutics, Inc. comes to $41.60. The forecasts range from a low of $39.00 to a high of $45.00. The average price target represents an increase of 139.63% from the last closing price of $17.36.
Analyst Price Targets (5 )
Broker Rating
Cartesian Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 71.43%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.43 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
8/6/2024 | Cowen & Co. | Tyler Van Buren | Not Available | Strong Buy |
7/8/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Strong Buy |
7/3/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
7/2/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/17/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
4/23/2024 | SVB Securities | Thomas J Smith | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $41.60 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 87 of 253 |
Current Quarter EPS Est: | -0.78 |
RNAC FAQs
Cartesian Therapeutics, Inc. (RNAC) currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Cartesian Therapeutics, Inc. (RNAC) is $41.60. The current on short-term price targets is based on 2 reports.
The forecasts for Cartesian Therapeutics, Inc. (RNAC) range from a low of $39 to a high of $45. The average price target represents a increase of $139.63 from the last closing price of $17.36.
The current UPSIDE for Cartesian Therapeutics, Inc. (RNAC) is 139.63%
Based on short-term price targets offered by five analysts, the average price target for Cartesian Therapeutics, Inc. comes to $41.60. The forecasts range from a low of $39.00 to a high of $45.00. The average price target represents an increase of 139.63% from the last closing price of $17.36.